Teclistamab is now an option after progression on triple-class therapy; however, the FDA also issued a Boxed Warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity.
U S FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Advancing Precision Medicine with Patient Data globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
Today, the Multiple Myeloma Research Foundation (MMRF) announced that new insights related to novel targets, risk assessment, and precision medicine approaches generated through the use of the MMRF landmark CoMMpass Study will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. In total, ASH will feature 33 presentations developed through the work of more than 200 researchers from 180 institutions all using the CoMMpass data. - Click here if this is your press release! - eTurboNews | Trends | Travel News